Upside, Downside Movers in the Morning

Upside

– $XNCR +32% (Phase 1 XmAb819 kidney-cancer data showed a 45.5% confirmed response rate and 82% six-month PFS at the proposed Phase 3 dose)

– $RENT +30% (no clear fresh catalyst identified; unusually heavy premarket volume extends Friday’s surge)

– $SGRY +24% (report of late-stage talks for Bon Secours Mercy Health to acquire a controlling stake at about $20 a share)

– $RRC +11% (EQT agreed to acquire it in a 0.987-share all-stock deal)

– $MACI +10% (shareholders approved the Everli business combination)

– $ROST +3.4% (UBS upgrades to Buy)

– $AVBP +3.3% (initial Phase 1 ARR-217 data showed a 44.8% response rate in colorectal cancer at the selected dose)

– $TSLA +2.3% (Barclays upgrades to Overweight, citing improving auto fundamentals, robotaxi momentum and potential SpaceX-combination upside)

Downside

– $XP -48%, $STNE -39%, $PAGS -32%, $BBD -30%, $ITUB -26%, $NU -26% (Brazil-linked financials plunge after leftist incumbent Lula won the presidential election over Flávio Bolsonaro)

– $BAK -34%, $PBR -19%, $VALE -4.9% (Brazil commodity names fall on the election shock and policy-risk repricing)

– $MRNA -8.1% (sell-the-news unwind continues after Phase 3 melanoma-vaccine data, with expectations elevated following the prior rally)

– $EQT -6.8% (falls as the acquirer in the all-stock purchase of RRC)

– $EFX -3.5% (RBC downgrades to Sector Perform on mortgage weakness concerns)

– $NTAP 3.0% (Guggenheim initiates coverage at Neutral)

– $CRWV -2.2%, $IREN -2.0% (neoclouds fall after SpaceX closed a $40B debt raise to buy Nvidia GPUs, signaling a large captive AI-compute build)

Upside, Downside Movers in the Morning

Upside

– $ALEC +58% (global AL050 license brings $100M upfront, up to $1.17B in milestones and extends the cash runway into 2029)

– $PCVX +55% (VAX-31 OPUS-1 pivotal Phase 3 trial met all prespecified primary endpoints with a safety profile comparable to existing vaccines)

– $PTC +36% (agrees to a $205-a-share all-cash takeover valuing its equity at about $22.6B)

– $RXO +23% (agrees to a $5.8B cash-and-stock takeover by $CHRW, implying about $30.25 a share)

– $XP +17%, $BBD +12%, $NU +13%, $ITUB +14%, $PBR +9.4%, $EMBJ +5.4% (Brazil-linked ADRs surge after the right-wing candidate outperformed polls and led first-round presidential voting)

– $ADSK +4.4% (industrial-software M&A read-through from the PTC takeover)

– $VST +3.5% (reported $4.2B federal loan package expected to fund upgrades at three nuclear plants)

Downside

– $CHRW -7.6% ($RXO acquisition requires new debt and a buyback pause while the market weighs execution and integration risk)

– $INTC -3.8% (no clear fresh company catalyst identified as chip shares lag softer technology futures)

– $ALGN -3.1% (no clear fresh company-specific catalysts identified; notable liquid premarket declines)

Upside, Downside Movers in the Morning

Upside

– $MEDS +36% (preliminary September pharmacy revenue exceeded $1M, rising more than 66% from July)

– $ACN +17% (Q4 beat with $22.2B of bookings and stronger operating margins)

– $ABAT +13% (receives federal approval to export up to $100M of recycled black-mass material)

– $QSI +13% (no clear fresh catalyst identified; unusually large move on heavy premarket volume)

– $VICR +12% (raises Q3 sequential revenue-growth outlook to more than 30% from more than 20% on higher royalties)

– $GLOB +11%, $CTSH +7.5%, $INFY +8.1%, $EPAM +6.6% (IT-services names rise in read-through from ACN’s Q4 beat, strong bookings and margin performance)

– $INSG +9.6% (completes fixed-wireless-access acquisition expected to roughly double revenue and expand its global footprint)

– $IBM +5.7% (unveils a self-hosted enterprise AI model)

– $NU +5.6% (rebounds after clarifying it is not pursuing the reported UK digital-bank acquisition)

– $GLUE +4.8% (Phase 1 GFORCE-1 results showed normalization of key pathogenic drivers of cardiovascular disease)

– $RKLB +4.3% (signs its largest commercial launch agreement, covering 20 missions and lifting total backlog above 100 launches)

– $MKC +3.7% (Q3 profit and sales beat expectations as pricing offset softer volumes)

– $SNPS +3.7% (signs a multiyear silicon-IP and engineering-software agreement valued above $1B)

– $CEG +3.4% (signs a 20-year, 690-megawatt nuclear power agreement supporting more than $3B of infrastructure investment)

– $TARA +3.3% (updated 12-month Phase 2 ADVANCED-2 data showed durable responses in BCG-naïve bladder-cancer patients)

Downside

– $FHTX -43% (Phase 1 review leads to discontinuation of FHD-909 expansion and a related degrader program; workforce cut about 40%)

– $ANGO -16% (no clear fresh catalyst identified; unusually large, high-volume premarket decline)

– $LQDA -12% (federal court rules YUTREPIA infringed two pulmonary-hypertension patent claims)

– $ZELA -12% (Phase 3 obesity trial met its endpoints, but weight-loss efficacy fell short of investor expectations)

– $BGIN -10% (slides following first-half results)

– $IVA -10% (extends weakness following unaudited first-half results and corporate update)

– $FLOC -8.5% (no clear fresh catalyst identified; unusually large, liquid premarket decline)

– $ENTX -6.4% (no clear fresh catalyst identified after healthcare and company-news checks)